| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The compound acts as a non-selective serotonin receptor agonist, with high affinity for the 5-HT2A receptor (Ki ~ 50-100 nM). It also acts as a serotonin reuptake inhibitor and a monoamine oxidase A (MAO-A) inhibitor, leading to increased synaptic serotonin levels.
|
|---|---|
| ln Vitro |
In vitro, 5-Methoxy-alpha-ethyltryptamine binds to human 5-HT2A, 5-HT2C, and 5-HT1A receptors with moderate affinity. It inhibits serotonin reuptake in synaptosomal preparations with IC50 values in the low micromolar range and inhibits MAO-A activity.
|
| ln Vivo |
In vivo, the compound produces the head-twitch response in rodents (a behavioral correlate of human hallucinogenesis) and increases locomotor activity at lower doses. High doses can induce serotonin syndrome-like effects including hyperthermia, tremor, and autonomic instability.
|
| Enzyme Assay |
Not specified for this compound. Standard receptor binding assays are performed using membrane preparations from HEK-293 cells expressing human 5-HT2A receptors. Competition with [3H]ketanserin or [3H]LSD is measured, and bound radioactivity is quantified by filtration.
|
| Cell Assay |
Standard uptake inhibition assays: Rat brain synaptosomes or HEK-293 cells expressing SERT are incubated with [3H]serotonin and the compound. After incubation, the reaction is terminated by filtration, and accumulated radioactivity is counted to determine uptake inhibition.
|
| Animal Protocol |
In vivo behavioral assays typically use male Sprague-Dawley rats or C57BL/6 mice. The compound is administered intraperitoneally, and the number of head twitches is counted over 20-30 minutes. Locomotor activity is recorded using photobeam chambers or video tracking.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are limited. Tryptamines generally have rapid absorption and brain penetration. The compound is metabolized primarily by MAO-A and CYP2D6, with an estimated half-life of 2-4 hours in rodents. N-dealkylation and O-demethylation are major pathways.
|
| Toxicity/Toxicokinetics |
Toxicology: At high doses, the compound can cause serotonin toxicity, including hyperthermia, seizures, and rhabdomyolysis. Chronic use may lead to valvular heart disease due to 5-HT2B receptor agonism. There is potential for neurotoxicity similar to other substituted tryptamines.
|
| References |
[1]. Ventura MI, et al. Revealing the presence of tryptamine new psychoactive substances using fused "neutral loss" spectra derived from DART high-resolution mass spectra. Talanta. 2022 Aug 15;246:123417.
|
| Additional Infomation |
This compound is a research chemical and a controlled substance in many countries. It has no approved medical use. It is structurally related to alpha-ethyltryptamine (AET), which was briefly used as an antidepressant in the 1960s but withdrawn due to toxicity.
|
| Molecular Formula |
C13H18N2O
|
|---|---|
| Molecular Weight |
218.29
|
| Exact Mass |
218.141
|
| CAS # |
4765-10-0
|
| PubChem CID |
13679707
|
| Appearance |
Off-white to brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
393.3±27.0 °C at 760 mmHg
|
| Flash Point |
191.6±23.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
2.18
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(CC1=CNC2=C1C=C(C=C2)OC)N
|
| InChi Key |
JHTPCKWBFLMJMQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18N2O/c1-3-10(14)6-9-8-15-13-5-4-11(16-2)7-12(9)13/h4-5,7-8,10,15H,3,6,14H2,1-2H3
|
| Chemical Name |
1-(5-methoxy-1H-indol-3-yl)butan-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (458.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5811 mL | 22.9053 mL | 45.8106 mL | |
| 5 mM | 0.9162 mL | 4.5811 mL | 9.1621 mL | |
| 10 mM | 0.4581 mL | 2.2905 mL | 4.5811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
